tetano
Editor, Senior Moderator
Microbiol Spectr
. 2022 Oct 12;e0059722.
doi: 10.1128/spectrum.00597-22. Online ahead of print.
One-Year Follow-Up of COVID-19 Patients Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2 Antibodies
Alexander E Egger[SUP] 1 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Andreas Gleiss[SUP] 3 [/SUP], Franz Ratzinger[SUP] 4 [/SUP], Barbara Holzer[SUP] 5 [/SUP], Christian Irsara[SUP] 1 [/SUP], Nikolaus Binder[SUP] 6 [/SUP], Christoph Winkler[SUP] 1 [/SUP], Christoph J Binder[SUP] 7 [/SUP], Wilfried Posch[SUP] 8 [/SUP], Lorin Loacker[SUP] 1 [/SUP], Boris Hartmann[SUP] 5 [/SUP], Markus Anliker[SUP] 1 [/SUP], Guenter Weiss[SUP] 2 [/SUP], Thomas Sonnweber[SUP] 2 [/SUP], Ivan Tancevski[SUP] 2 [/SUP], Andrea Griesmacher[SUP] 1 [/SUP], Judith Löffler-Ragg[SUP] 2 [/SUP], Gregor Hoermann[SUP] 1 9 [/SUP]
Affiliations
Abstract
Determination of antibody levels against the nucleocapsid (N) and spike (S) proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to estimate the humoral immune response after SARS-CoV-2 infection or vaccination. Differences in the design and specification of antibody assays challenge the interpretation of test results, and comparative studies are often limited to single time points per patient. We determined the longitudinal kinetics of antibody levels of 145 unvaccinated coronavirus disease 2019 (COVID-19) patients at four visits over 1 year upon convalescence using 8 commercial SARS-CoV-2 antibody assays (from Abbott, DiaSorin, Roche, Siemens, and Technoclone), as well as a virus neutralization test (VNT). A linear regression model was used to investigate whether antibody results obtained in the first 6 months after disease onset could predict the VNT results at 12 months. Spike protein-specific antibody tests showed good correlation to the VNT at individual time points (r[SUB]S[/SUB], 0.74 to 0.92). While longitudinal assay comparison with the Roche Elecsys anti-SARS-CoV-2 S test showed almost constant antibody concentrations over 12 months, the VNT and all other tests indicated a decline in serum antibody levels (median decrease to 14% to 36% of baseline). The antibody level at 3 months was the best predictor of the VNT results at 12 months after disease onset. The current standardization to a WHO calibrator for normalization to binding antibody units (BAU) is not sufficient for the harmonization of SARS-CoV-2 antibody tests. Assay-specific differences in absolute values and trends over time need to be considered when interpreting the course of antibody levels in patients. IMPORTANCE Determination of antibodies against SARS-CoV-2 will play an important role in detecting a sufficient immune response. Although all the manufacturers expressed antibody levels in binding antibody units per milliliter, thus suggesting comparable results, we found discrepant behavior between the eight investigated assays when we followed the antibody levels in a cohort of 145 convalescent patients over 1 year. While one assay yielded constant antibody levels, the others showed decreasing antibody levels to a varying extent. Therefore, the comparability of the assays must be improved regarding the long-term kinetics of antibody levels. This is a prerequisite for establishing reliable antibody level cutoffs for sufficient individual protection against SARS-CoV-2.
Keywords: SARS-CoV-2; antibody kinetics; assay comparison; neutralizing antibodies; predictive modelling.
. 2022 Oct 12;e0059722.
doi: 10.1128/spectrum.00597-22. Online ahead of print.
One-Year Follow-Up of COVID-19 Patients Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2 Antibodies
Alexander E Egger[SUP] 1 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Andreas Gleiss[SUP] 3 [/SUP], Franz Ratzinger[SUP] 4 [/SUP], Barbara Holzer[SUP] 5 [/SUP], Christian Irsara[SUP] 1 [/SUP], Nikolaus Binder[SUP] 6 [/SUP], Christoph Winkler[SUP] 1 [/SUP], Christoph J Binder[SUP] 7 [/SUP], Wilfried Posch[SUP] 8 [/SUP], Lorin Loacker[SUP] 1 [/SUP], Boris Hartmann[SUP] 5 [/SUP], Markus Anliker[SUP] 1 [/SUP], Guenter Weiss[SUP] 2 [/SUP], Thomas Sonnweber[SUP] 2 [/SUP], Ivan Tancevski[SUP] 2 [/SUP], Andrea Griesmacher[SUP] 1 [/SUP], Judith Löffler-Ragg[SUP] 2 [/SUP], Gregor Hoermann[SUP] 1 9 [/SUP]
Affiliations
- PMID: 36222681
- DOI: 10.1128/spectrum.00597-22
Abstract
Determination of antibody levels against the nucleocapsid (N) and spike (S) proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to estimate the humoral immune response after SARS-CoV-2 infection or vaccination. Differences in the design and specification of antibody assays challenge the interpretation of test results, and comparative studies are often limited to single time points per patient. We determined the longitudinal kinetics of antibody levels of 145 unvaccinated coronavirus disease 2019 (COVID-19) patients at four visits over 1 year upon convalescence using 8 commercial SARS-CoV-2 antibody assays (from Abbott, DiaSorin, Roche, Siemens, and Technoclone), as well as a virus neutralization test (VNT). A linear regression model was used to investigate whether antibody results obtained in the first 6 months after disease onset could predict the VNT results at 12 months. Spike protein-specific antibody tests showed good correlation to the VNT at individual time points (r[SUB]S[/SUB], 0.74 to 0.92). While longitudinal assay comparison with the Roche Elecsys anti-SARS-CoV-2 S test showed almost constant antibody concentrations over 12 months, the VNT and all other tests indicated a decline in serum antibody levels (median decrease to 14% to 36% of baseline). The antibody level at 3 months was the best predictor of the VNT results at 12 months after disease onset. The current standardization to a WHO calibrator for normalization to binding antibody units (BAU) is not sufficient for the harmonization of SARS-CoV-2 antibody tests. Assay-specific differences in absolute values and trends over time need to be considered when interpreting the course of antibody levels in patients. IMPORTANCE Determination of antibodies against SARS-CoV-2 will play an important role in detecting a sufficient immune response. Although all the manufacturers expressed antibody levels in binding antibody units per milliliter, thus suggesting comparable results, we found discrepant behavior between the eight investigated assays when we followed the antibody levels in a cohort of 145 convalescent patients over 1 year. While one assay yielded constant antibody levels, the others showed decreasing antibody levels to a varying extent. Therefore, the comparability of the assays must be improved regarding the long-term kinetics of antibody levels. This is a prerequisite for establishing reliable antibody level cutoffs for sufficient individual protection against SARS-CoV-2.
Keywords: SARS-CoV-2; antibody kinetics; assay comparison; neutralizing antibodies; predictive modelling.